// App-Quantinova.ai

3059 : Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors.

Researchers

Presenter

  • Antonio Calles

Principal Investigators

  • Irene Brana

  • Patricia Lo Russo

  • Lorrin Yee

  • Thomas Puchalski

  • Shobha Seetharam

  • Melan Balvers

  • Carla De Boer

  • Yusri A. Elsayed

  • Emiliano Calvo

  • Josep Tabernero

Medical Centers

  • Janssen Biologics, Leiden, Netherlands

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • OrthoBiotech Oncology Research and Development, Malvern, PA

  • Northwest Medical Specialists PLLC, Tacoma, WA

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Karmanos Cancer Institute, Detroit, MI

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Janssen Research and Development, LLC, Spring House, PA

Locations

  • United States

  • Spain

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • C-C Motif Chemokine Ligand 2

  • Circulating tumor cells

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • Doxorubicin

  • Paclitaxel

  • Docetaxel

  • carlumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved